Study Highlights Insurance-Based Disparities in TEVAR for TBAD

April 21, 2026—In this retrospective analysis, Zil-E-Ali et al found that patients with government-funded insurance who underwent urgent or emergent thoracic endovascular aortic repair (TEVAR) for type B aortic dissection (TBAD) presented with more advanced disease and experienced significantly higher short- and long-term mortality than commercially insured patients.

Elucid Introduces Lesion Inspection Tool for Plaque-IQ Software Suite

April 20, 2026—Elucid announced the commercial availability of a new lesion inspection tool for coronary and carotid plaque analysis in its Plaque-IQ software suite.

VIRad.AI Launches Clinical Decision Support Platform for Interventional Radiology

April 17, 2026—VIRad.AI announced the launch of its artificial intelligence (AI)–powered clinical decision support platform, designed specifically for interventional radiology.

Bayer’s Asundexian FXIa Inhibitor Demonstrates Reduction in Ischemic Stroke in OCEANIC-STROKE Study

April 17, 2026—The results from the OCEANIC-STROKE study were published by Mukul Sharma, MD, et al in The New England Journal of Medicine (NEJM; 2026;394:1467-1479).

Rapid Medical’s Tigertriever 25 Cleared by FDA to Treat LVO Stroke

April 16, 2026—Rapid Medical announced FDA clearance of the Tigertriever 25 thrombectomy device.

Stereotaxis to Acquire Robocath

April 15, 2026–Stereotaxis, a St. Louis, Missouri–based company focused on robotics for endovascular intervention, announced that it has entered into a definitive agreement to acquire Robocath.

Medtronic’s IN.PACT AV Access Postapproval Study Reports 12-Month Outcomes

April 15, 2026—Medtronic announced that 12-month findings from the IN.PACT AV Access postapproval study of the company’s In.Pact AV drug-coated balloon (DCB) demonstrated the device’s safety and effectiveness in the treatment of arteriovenous (AV) fistula stenoses in patients with end-stage renal disease (ESRD) on dialysis.

Data Presented for Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP Therapy Platform

April 14, 2026—RenovoRx, Inc., which is developing targeted oncology therapies and commercializing its FDA-cleared RenovoCath drug-delivery device, announced findings on the effectiveness of local, targeted intra-arterial chemotherapy administration using the company’s transarterial microperfusion therapy (TAMP) platform.